Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Revenue (2020 - 2025)

Apellis Pharmaceuticals has reported Revenue over the past 6 years, most recently at $199.9 million for Q4 2025.

  • Quarterly results put Revenue at $199.9 million for Q4 2025, down 5.94% from a year ago — trailing twelve months through Dec 2025 was $1.0 billion (up 28.46% YoY), and the annual figure for FY2025 was $1.0 billion, up 28.46%.
  • Revenue for Q4 2025 was $199.9 million at Apellis Pharmaceuticals, down from $458.6 million in the prior quarter.
  • Over the last five years, Revenue for APLS hit a ceiling of $458.6 million in Q3 2025 and a floor of $623000.0 in Q2 2021.
  • Median Revenue over the past 5 years was $110.4 million (2023), compared with a mean of $122.3 million.
  • Biggest five-year swings in Revenue: plummeted 75.88% in 2021 and later surged 2519.9% in 2022.
  • Apellis Pharmaceuticals' Revenue stood at $60.3 million in 2021, then plummeted by 62.41% to $22.7 million in 2022, then surged by 545.89% to $146.4 million in 2023, then surged by 45.19% to $212.5 million in 2024, then decreased by 5.94% to $199.9 million in 2025.
  • The last three reported values for Revenue were $199.9 million (Q4 2025), $458.6 million (Q3 2025), and $178.5 million (Q2 2025) per Business Quant data.